| Wu, Yan |
NCT05463965: A Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 605 | RoW | QM1114-DP, OnabotulinumtoxinA, Placebo | Galderma R&D | Moderate to Severe Glabellar Lines | 01/23 | 06/23 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
NCT06499688: A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Completed | 3 | 529 | RoW | Rcombinant botulinum neurotoxin type A for injection (YY001), OnabotulinumtoxinA, Placebo | Chongqing Claruvis Pharmaceutical Co., Ltd. | Moderate to Severe Glabellar Lines | 03/24 | 05/24 | | |
NCT06583486: A Study on the Efficacy and Safety of Repeated Treatments With Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines |
|
|
| Active, not recruiting | 3 | 488 | RoW | Rcombinant botulinum neurotoxin type A for injection (YY001) | Chongqing Claruvis Pharmaceutical Co., Ltd. | Moderate to Severe Glabellar Lines | 08/25 | 08/25 | | |
NCT06585696: A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type a for Injection (CU-20101) |
|
|
| Recruiting | 3 | 554 | RoW | CU-20101 treatment for Moderate to Severe Glabellar Striae | Cutia Therapeutics（Wuxi）Co.,Ltd | Glabellar Frown Lines | 03/26 | 05/26 | | |
| Recruiting | 3 | 189 | RoW | Roflumilast Cream 0.3%, Zoryve, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Plaque Psoriasis | 06/25 | 07/25 | | |
NCT06631170: Efficacy and Safety of Roflumilast Cream in Subjects with Atopic Dermatitis |
|
|
| Recruiting | 3 | 351 | RoW | Roflumilast Cream 0.15%, Vehicle cream | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Atopic Dermatitis (AD) | 08/25 | 08/25 | | |
NCT06738979: A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects |
|
|
| Not yet recruiting | 3 | 408 | RoW | TQF3510 (Semaglutide Injection), Wegovy® | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Obesity | 07/26 | 08/26 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
AK3280-2002, NCT05424887: A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis |
|
|
| Not yet recruiting | 2 | 105 | RoW | AK3280, Placebo | Ark Biosciences Inc., Shanghai Ark Biopharmaceutical Co., Ltd. | Idiopathic Pulmonary Fibrosis | 07/24 | 10/24 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
NCT05434897: A Study to Evaluate the Safety, Tolerability and Efficacy of AK3280 Cream on Hypertrophic Scar |
|
|
| Not yet recruiting | 1/2 | 30 | RoW | AK3280 Cream, AK3287, Placebo cream | Ark Biosciences Inc., Shanghai Ark Biopharmaceutical Co., Ltd. | Hypertrophic Scar | 07/23 | 11/23 | | |
NCT04861766: Safety and Effectiveness of STYLAGE® L for Correction of Moderate and Severe Nasolabial Folds in Chinese Adults |
|
|
| Completed | N/A | 390 | RoW | STYLAGE® L, Active Comparator | Laboratoires Vivacy | Aging, Skin Wrinkling | 08/22 | 03/23 | | |
NCT05009381: Effectiveness and Safety of STYLAGE® XXL for Chin Augmentation in Chinese Adults |
|
|
| Completed | N/A | 174 | RoW | Stylage XXL at enrollment, Stylage XXL at Month 6 | Laboratoires Vivacy | Esthetic | 10/22 | 08/23 | | |
| Recruiting | N/A | 30000 | RoW | | Beijing Jishuitan Hospital, Chinese PLA General Hospital, Ruijin Hospital, Huashan Hospital, Henan Provincial People's Hospital, The Affiliated Hospital Of Guizhou Medical University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, The First Affiliated Hospital of Zhengzhou University, First Affiliated Hospital Xi'an Jiaotong University, The renmin hospital of wuhan university, Nanjing BenQ Hospital, China-Japan Friendship Hospital, xinan hospital, Wu Hu Yijishan hospital, The fifth affiliated hospital of zhong shan university | Osteoporosis, Obesity, Liver Steatoses | 06/23 | 12/23 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
